Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models

Cancer Research

Volumn 76, Issue 10, 2016, Pages 3003-3013

  Challita Eid, Pia M ^a   Satpayev, Daulet ^a   Yang, Peng ^a   An, Zili ^a   Morrison, Karen ^a   Shostak, Yuriy ^a   Raitano, Arthur ^a   Nadell, Rossana ^a   Liu, Wendy ^a   Lortie, Dawn Ratay ^a   Capo, Linnette ^a   Verlinsky, Alla ^a   Leavitt, Monica ^a   Malik, Faisal ^a   Avina, Hector ^a   Guevara, Claudia I ^a   Dinh, Nick ^a   Karki, Sher ^a   Anand, Banmeet S ^a   Pereira, Daniel S ^a   Joseph, Ingrid B J ^a   Donate, Fernando ^a   Morrison, Kendall ^a   Stover, David R ^a   more..

^a Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFORTUMAB VEDOTIN; MEMBRANE PROTEIN; NECTIN 4; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; NECTINS; OLIGOPEPTIDE; VEDOTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLADDER CANCER; BREAST CANCER; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; ESOPHAGUS TUMOR; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MACACA FASCICULARIS; METABOLISM; NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; RAT; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; IMMUNOENZYME TECHNIQUES; MACACA FASCICULARIS; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASMS; OLIGOPEPTIDES; RATS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971508139     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1313     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Nadal R, Bellmunt J.Newtreatments for bladder cancer: Whenwill we make progress?Curr Treat Options Oncol 2014;15:99-114.
3. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 2015; 41:170-8.
4. Beck A, Reichert JM. Antibody-drug conjugates: present and future. MAbs 2014;6:15-7.
5. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-32.
6. Younes A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol Oncol Clin North Am 2014;28:27-32.
7. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
8. Dhillon S. Trastuzumab emtansine: A review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab- based therapy. Drugs 2014;74:675-86.
9. Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014;20: 4436-41.
10. Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci 2015;72:645-58.
11. Mori M, Rikitake Y, Mandai K, Takai Y. Roles of nectins and nectin-like molecules in the nervous system. Adv Neurobiol 2014;8:91-116.
12. Rikitake Y, Mandai K, Takai Y. The role of nectins in different types of cellcell adhesion. J Cell Sci 2012;125:3713-22.
13. Blackwood EM, Lugo TG, Kretzner L, King MW, Street AJ, Witte ON, et al. Functional analysis of the AUG- And CUG-initiated forms of the c-Myc protein. Mol Biol Cell 1994;5:597-609.
14. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231:11-23.
15. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
16. Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther 2014;13: 2991-3000.
17. Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 2013;15:1138-50.
18. Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
19. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin-associated member of the nectin family that transinteracts with nectin1/PRR1 through V domain interaction. J Biol Chem 2001;276:43205-15.
20. Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G, et al. Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem 2002;277:27006-13.
21. Delpeut S, Noyce RS, Richardson CD. The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses. Viruses 2014;6: 2268-86.
22. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530-3.
23. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011;49:26-33.
24. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703.
25. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73.
26. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134:835-45.
27. Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007;18:477-85.
28. Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, et al. Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry 2013;52:4531-40.
29. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta 2012;1826:199-208.
30. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 2012;38:133-42.
31. Ghedini GC, Ciravolo V, Tortoreto M, Giuffre S, Bianchi F, Campiglio M, et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol 2010;225:256-65.
32. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009;27:1685-93.
33. Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife 2013;2:e00358.